Brus
★    

Spain,
2023-12-09 18:45
(280 d 02:53 ago)

Posting: # 23790
Views: 1,881
 

 Single-dose study in patients [Design Issues]

Post reply
Dear All,

When you need to perform the study in patients due to tolerability/safety reasons, How do you perform the washout period in patients? (Between periods and before period 1 to avoid pre-dose concentrations in both periods).

Thank you so much

Best regards,
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2023-12-10 10:43
(279 d 10:56 ago)

@ Brus
Posting: # 23791
Views: 1,515
 

 Single-dose study in patients

Post reply
Hi Brus,

❝ When you need to perform the study in patients due to tolerability/safety reasons, How do you perform the washout period in patients? (Between periods and before period 1 to avoid pre-dose concentrations in both periods).


A SD crossover is only possible for drugs in patients with a stable disease (e.g., theophylline in asthmatics). Otherwise, you have to opt for a parallel design.
  • Get PK data from the literature. Don’t use the average half life, be conservative (example).
  • Plan the study (first dose after the patients’ usual treatment, washout) with ≥ 5 × t½. If that’s longer than the common dosing interval → SD not possible.
  • Simulate concentrations (in Phoenix / Win­Non­lin’s ‘nonparametric superpostion’ module or even a spreadsheet) with your dose & regimen. If you would get pre-dose concentrations > 5% of Cmax in a substantial number of subjects → SD not possible.
  • If a SD study is not possible, you have to perform the study in steady state. Sorry.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
dshah
★★  

India,
2023-12-11 11:44
(278 d 09:54 ago)

@ Brus
Posting: # 23792
Views: 1,592
 

 Single-dose study in patients

Post reply
Hi Brus!

❝ When you need to perform the study in patients due to tolerability/safety reasons, How do you perform the washout period in patients? (Between periods and before period 1 to avoid pre-dose concentrations in both periods).


Generally the patient study is required to be performed for stabilized patient. How can treatment be discontinued in patient?

Regards,
Divyen
 
UA Flag
Activity
 Admin contact
23,225 posts in 4,879 threads, 1,652 registered users;
44 visitors (0 registered, 44 guests [including 9 identified bots]).
Forum time: 22:39 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5